The market value has doubled: why the pioneering pharmaceutical industry is flying against the wind

The outbreak of the new crown epidemic has given a group of pharmaceutical companies a bonus

Kaixing Pharmaceutical is a clinical-stage new drug developer established in March 2009, focusing on the independent research and development of potential first-in-class and best-in-class cancer drugs and other androgen receptor (AR) related disease drugs

Under such a background, it seems that the pioneering pharmaceutical industry has always been sought after by capital.

New prostate cancer drugs are about to be commercialized

The core of the pioneering pharmaceutical industry is the treatment of prostate cancer, breast cancer, liver cancer and hair loss, with AR-related diseases as the core

Open up the pharmaceutical R&D pipeline (Image source: Open up the pharmaceutical official website)

Prokrulide is the second-generation AR antagonist and the core product of the pioneering pharmaceutical industry.

At the beginning of March of this year, Pioneer Pharmaceuticals announced that the clinical trial of procrulamide in the treatment of severely ill patients with new crown in Brazil reached the primary endpoint

Procruamide market prospects-prostate cancer

The first indication for Prokalamide is prostate cancer, which is one of the most common types of cancer in the male population.

Source: Frost & Sullivan Report

According to the Frost & Sullivan report, the Chinese prostate cancer drug market has grown from RMB 1.

Procruamide market prospects-breast cancer

Prokalamide's second indication is breast cancer, which is one of the most common cancers in the female population

Source: Frost & Sullivan Report

Although more than 50% of breast cancer patients are AR+, no AR antagonist has been approved for the treatment of metastatic breast cancer

Freetarin-Seeking innovative treatments for patients with androgen

Freetann is an AR antagonist specially designed for topical application, developed by Pioneer Pharmaceuticals for the treatment of androgenetic alopecia

In China, there are more than 92.

At present, there are only two drugs approved by the US FDA for the treatment of androgenetic alopecia, namely finasteride approved in 1997 and minoxidil approved in 1988

Comparing with the existing drugs on the market, Phrayton has better advantages and safety.

ALK-1 monoclonal antibody

ALK-1.

In in vitro pharmacological tests, GT90001 has high affinity and specificity with human ALK-1

In 2018, Kaifeng Pharmaceutical obtained the exclusive rights to GT90001 from Pfizer Inc.
, and it is expected to become the world's first fully human monoclonal antibody therapeutic drug targeting ALK-1
.
The drug is currently undergoing phase II clinical trials in combination with PD-1 in the treatment of metastatic hepatocellular carcinoma in Taiwan, China
.

PROTAC degradation agent——GT20029

GT20029 is a new type of PROTAC AR degradation agent, which can effectively block the signal pathway of androgen receptor and its physiological functions by degrading AR protein
.

GT20029 is the world's first topical PROTAC compound that has entered the clinical stage.
It was approved by the China Food and Drug Administration for Phase I clinical trials in April 2021, and it has also entered the clinical stage in the United States
.
The clinical trial is a randomized, double-blind, placebo-controlled, parallel grouping, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of GT20029 after local single and multiple dose escalation
.

Excessive activation of the androgen receptor pathway is an important link in the pathogenesis of androgenic alopecia and acne
.
GT20029 can effectively block the signal pathway of androgen receptor and its physiological functions by degrading the androgen receptor protein
.
The effectiveness of GT20029 in preclinical studies is superior to other small molecule AR antagonists.
While producing local curative effects, GT20029 can effectively reduce systemic drug exposure and avoid the side effects of related oral therapeutic drugs
.

Development Pharmaceuticals started to deploy PROTAC in 2018.
GT20029 is an innovative drug for external use developed based on the PROTAC platform.
This is another international clinical trial license obtained by the company after the FDA has just agreed to start a phase II clinical trial of Fritan.
The international layout of innovative drug pipelines
.

In the prospectus, Kaifeng Pharmaceutical explained its recent plans after listing
.
The company is committed to becoming a global leader in the research, development and commercialization of innovative therapies, focusing on disease fields that have not met clinical needs, especially AR related fields
.

Pioneer Pharmaceuticals will accelerate the clinical development, regulatory approval, and commercialization of Prokrutamide in China, strategically promote the clinical development of Furitan in China and the United States, and ALK-1 antibody as a monotherapy and combination The clinical development of therapies, and increase the company's attention to the research and development of biological drugs
.

In the past 10 years, the pioneering pharmaceutical industry has deeply cultivated AR, ALK-1 and other targets, and has researched innovative treatments in large cancers such as prostate cancer, breast cancer, liver cancer, and seborrheic alopecia and acne.
Achieved results
.
In the next 10 years, Pioneer Pharmaceuticals will continue to base itself on the Chinese and American markets, develop a variety of single-drug and combined innovative therapies, and become a global leader in effective treatment of diseases with huge and unmet needs
.

refer to:

1.
Retrieved Feb.
21.
2020.

from http:// http:// 2.
Retrieved Dec.
31.
2019.

from https://www1.
hkexnews.
hk/app/sehk/2019/101088/documents/sehk19123101995_e.
pdf.

3.
Open up the prospectus of the pharmaceutical industry
.